Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Authors:
Open Access
- 19 December 2011
- journal article
- research article
- Published by Wiley in Advances in Urology
- Vol. 2012, 1-8
Abstract
Aim. The aim of this study is to present the oncologic outcomes and to determine the prognostic factors of overall survival (OS), cancer-specific survival (CSS), disease-progression-free survival (DPFS), and biochemical-progression-free survival (BPFS) after surgery for pT3 prostate cancer (PCa).Methods. Between 2002 and 2007, a pT3 stage after radical prostatectomy was detected in 182 patients at our institution. The Kaplan-Meier analysis was used to calculate OS, CSS, DPFS, and BPFS. Cox regression was used to identify predictive factors of survival.Results. pT3a was detected in 126 (69%) and pT3b in 56 (31%) of cases. Five-year OS, CSS, DPFS, and BPFS rates were 90.7%, 94%, 91.8%, and 48.4%, respectively. Survival was significantly different when comparing pT3a to pT3b groups. The 5-year OS, CSS, DPFS, and BPFS were 96% versus 72%, 98% versus 77%, 97.3% versus 79.3%, and 60% versus 24.2%, respectively. Specimen Gleason score was the most significant predictor of OS, CSS, DPFS, and BPFS. The risk of death increased up to 3-fold when a Gleason score 8–10 was present at the final pathology.Conclusions. Radical prostatectomy may offer very good CSS, OS, DPFS, and BPFS rates in pT3a PCa. However, outcomes in patients with pT3b or specimen Gleason ≥8 were significantly worse, suggesting the need for multimodality treatment in those cases.Keywords
This publication has 19 references indexed in Scilit:
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 PatientsEuropean Urology, 2010
- Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2009
- Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical ProstatectomyEuropean Urology, 2008
- An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate CancerEuropean Urology, 2008
- Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy—A Propensity Scoring ApproachJournal of Urology, 2007
- Poorly Differentiated Prostate Cancer Treated With Radical Prostatectomy: Long-Term Outcome and Incidence of Pathological DowngradingJournal of Urology, 2006
- Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcomeBJU International, 2005
- PROGRESSION IN AND SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (T3) TREATED WITH RADICAL PROSTATECTOMY AS MONOTHERAPYJournal of Urology, 1998
- PROGRESSION IN AND SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (T3) TREATED WITH RADICAL PROSTATECTOMY AS MONOTHERAPYJournal of Urology, 1998